<DOC>
	<DOCNO>NCT00256100</DOCNO>
	<brief_summary>The purpose project assess safety effectiveness fondaparinux , new drug prevent blood clot continuous dialysis machine use intensive care patient kidney failure .</brief_summary>
	<brief_title>Fondaparinux Anticoagulant Haemofiltration Patients With Acute Kidney Failure .</brief_title>
	<detailed_description>The study hypothesis use anticoagulant haemofiltration , fondaparinux prolongs filter life compare enoxaparin . Fondaparinux first compound new class synthetic oligosaccharide antithrombotic effect . It represent active portion natural heparin molecule . The null hypothesis difference filter life use fondaparinux enoxaparin anticoagulation haemofiltration .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>1 . Adult patient ( 18 year ) admit ICU expect stay 48 hour . 2 . Patients require continuous renal replacement therapy . 3 . Patients consent patient competent , next kin consent inclusion study . . 1 . Patients age less 18 year age . 2 . Patients pregnant 3 . Patients contraindication anticoagulation pre exist bleed diathesis 4 . Patients next kin consent study inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>